Mikkel Wandahl Pedersen

Chief Tech/Sci/R&D Officer at NYKODE THERAPEUTICS

50 year

Health Technology

Consumer Services

Profile

Mikkel Wandahl Pedersen is currently the Chief Scientific Officer at Nykode Therapeutics ASA since 2021.
Previously, he worked as the Chief Scientific Officer at Symphogen A.
He holds a doctorate degree from the University of Copenhagen.

Mikkel Wandahl Pedersen active positions

Companies	Position	Start
NYKODE THERAPEUTICS	Chief Tech/Sci/R&D Officer	01/06/2021

All active positions of Mikkel Wandahl Pedersen

Former positions of Mikkel Wandahl Pedersen

Companies	Position	End
Symphogen A/S Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.	Chief Tech/Sci/R&D Officer	-

See the detail of Mikkel Wandahl Pedersen's experience

Training of Mikkel Wandahl Pedersen

University of Copenhagen

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mikkel Wandahl Pedersen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
NYKODE THERAPEUTICS	Health Technology

Private companies	1
Symphogen A/S Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.	Health Technology